𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer

✍ Scribed by Hitoshi Tsuda; Setsuo Hirohashi


Publisher
John Wiley and Sons
Year
1994
Tongue
French
Weight
855 KB
Volume
57
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

In order to reveal whether differences in the type and site of p53 gene mutations influence the function of the gene and tumor phenotype, we examined nuclear accumulation of the p53 protein immunohistochemically, loss of the other p53 allele by restriction‐fragment‐length polymorphism analysis, and histological grade of atypia in 52 breast‐cancer tissue specimens in which the position and pattern of the mutation were identified. When mis‐sense point mutations ordeletionsof3nbases(n = 1, 2,…), which did not cause a frame shift downstream, occurred within codons 110‐180 or 234‐285, containing highly conserved regions, the p53 protein was almost always (92%) accumulated in nuclei in a majority of the cancer cells. When these mutations occurred outside these regions, only 46% of the cases showed nuclear accumulation of the protein in a majority of cancer cells. In tumors with non‐sense point mutations or deletion of 3n+1 or 3n + 2 bases (n = 0, 1, 2,…), which caused a downstream frameshift, nuclear accumulation of the p53 protein was absent in 93% of cases. Irrespective of the mutation site or pattern, a majority of cases showing p53 mutation revealed loss of hetero‐zygosity on 17p13 (83%), which suggested they do not carry wild‐type p53 allele, and the highest histological grade of atypia (90%). Regardless of differences in their protein‐expression pattern, a majority of the p53 gene mutations were suggested to function in a recessive mode and to be involved in the development of histologically aggressive breast cancer. © 1994 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Mutations of the p53 gene in male breast
✍ Agnaldo Anelli; Tǎnia F. M. Anelli; Bruce Youngson; Paul P. Rosen; Patrick I. Bo 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 609 KB
Correlations between p53-protein accumul
✍ Pascal Hammel; Karen Leroy-Viard; Marie-Thérèse Chaumette; Jacqueline Villaudy; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 254 KB 👁 1 views

Only half of colorectal-cancer patients elicit serum antibodies in response to intratumoral p53-gene mutations. Our study was designed to compare cellular events (p53-protein accumulation and gene mutations) with the presence of circulating anti-p53 antibodies (p53-Ab). Thirty-five colorectalcancer

Functional analysis of p53 gene and the
✍ Noriaki Sakuragi; Hidemichi Watari; Yasuhiko Ebina; Ritsu Yamamoto; Eric Steiner 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 182 KB 👁 1 views

## Abstract In addition to the loss of function, mutant p53 can possess a dominant‐negative effect on wild‐type p53 and may also exert gain‐of‐function activity. It is not clear whether the functional status of __p53__ mutation contributes to differences in outcome in endometrial cancer. We collect

Detection of p53 gene mutation by rapid
✍ Richie Soong; Barry J. Iacopetta; Jennet M. Harvey; Gregory F. Sterrett; Hugh J. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 73 KB 👁 2 views

We examined the association between mutation of the p53 gene and survival in a large cohort of breast cancer patients. Using a rapid, non-isotopic single-strand conformation polymorphism (SSCP) method we screened for mutations in exons 4-10 of the p53 gene in 375 primary breast cancers from patients

Comparison between p53 protein measureme
✍ Torbjörn Norberg; Johan Lennerstrand; Mats Inganäs; Jonas Bergh 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 120 KB 👁 2 views

The p53 mutational status of 226 representative primary breast cancer samples, derived from a population-based cohort, was analyzed using cDNA-based sequencing. The results were compared with those obtained with immunohistochemistry (IHC) on microwave-treated paraffin sections and the p53 specific l